TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07805707: A Phase 3 Randomized, Observer-Blind, Controlled Study to Evaluate the Clinical Efficacy of an mRNA Based Seasonal Influenza Vaccine in Older Adults ≥65 Years of Age

Sponsor: GlaxoSmithKline · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 54000 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$13,359,360

Rescue Site Savings

+$8,808,828

Unlock Full NCT07805707 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07805707 Rescue Dossier →